Search - tctmd.com

Displaying 141 - 160 of 167

Sort: Relevancy | Date

News Daily News

FH Screening Started at Time of Childhood Immunization Feasible and Effective

Michael O'Riordan

October 28, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Daily News

CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study

Michael O'Riordan

September 22, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Daily News

Review Touts Benefits of Statins, Seeks to Dispel Safety Concerns

Todd Neale

September 12, 2016

News Conference News ESC 2016

Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD

Todd Neale

September 09, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Daily News

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Michael O'Riordan

August 09, 2016

News Daily News

Underuse of Medical Therapy Linked With Increased Adverse Events in Very Elderly

Michael O'Riordan

July 21, 2016

News Daily News

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Michael O'Riordan

July 15, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

Todd Neale

June 22, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

News Daily News

No More Niacin, Fibrate Combinations With Statins: FDA

Michael O'Riordan

April 19, 2016

News Daily News

Performance Metrics Revised for Statins Post-MI, After PCI, and in CAD Patients

Michael O'Riordan

December 20, 2015

News Daily News

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Michael O'Riordan

December 15, 2015

News Daily News

没有钱就得不到药物：全球范围内心血管疾病二级预防的障碍

Caitlin E. Cox

October 27, 2015

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

News Daily News

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

February 25, 2013

Advertisement

FH Screening Started at Time of Childhood Immunization Feasible and Effective

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

Review Touts Benefits of Statins, Seeks to Dispel Safety Concerns

Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Underuse of Medical Therapy Linked With Increased Adverse Events in Very Elderly

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

No More Niacin, Fibrate Combinations With Statins: FDA

Performance Metrics Revised for Statins Post-MI, After PCI, and in CAD Patients

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

没有钱就得不到药物：全球范围内心血管疾病二级预防的障碍

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content